Literature DB >> 28597409

Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage.

Giulia Costa1, Micaela Morelli2,3, Nicola Simola1.   

Abstract

The amphetamine-related drug 3,4-methylenedioxymethamphetamine (MDMA) is known to induce neurotoxic damage in dopaminergic regions of the mouse brain. In order to characterize how the number of administrations influenced the severity of MDMA-induced dopaminergic damage and to describe the localization and persistence of this damage, we evaluated the changes in tyrosine hydroxylase (TH) and dopamine transporter (DAT) in different regions of the mouse brain. Moreover, we investigated whether dopaminergic damage was associated with noradrenergic, GABAergic, and serotonergic damage, by evaluating the changes in noradrenaline transporter (NET), glutamic acid decarboxylase-67 (GAD-67), and serotonin transporter (SERT). Mice received 14, 28, or 36 MDMA administrations (10 mg/kg twice a week) and were sacrificed at different time points (postnatal days 85, 110, 138, or 214) for immunohistochemical evaluation. Mice receiving 28 administrations showed reduced levels of DAT-positive fibers in caudate-putamen (CPu) and medial prefrontal cortex (mPFC) and reduced levels of TH-positive nigral neurons. These mice also displayed increased NET-positive hippocampal fibers, reduced GAD-67-positive neurons in CPu and hippocampus, and reduced GAD-67-positive fibers in mPFC. Similar effects of MDMA on DAT, TH, and GAD-67 were found in mice receiving 36 administrations, which also displayed reduced levels of striatal, cortical, and hippocampal TH-immunoreactive fibers. The reductions in dopaminergic markers and GAD-67 persisted at 3 months after MDMA discontinuation. Finally, MDMA never modified the levels of SERT. These results provide further insight into the localization and persistence of MDMA-induced dopaminergic damage and show that this effect may associate with GABAergic but not noradrenergic or serotonergic damage.

Entities:  

Keywords:  Amphetamine-related drugs; Dopamine transporter; Glutamic acid decarboxylase-67; Noradrenaline transporter; Serotonin transporter; Tyrosine hydroxylase

Mesh:

Substances:

Year:  2017        PMID: 28597409     DOI: 10.1007/s12640-017-9761-6

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  57 in total

1.  Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice.

Authors:  Clara Ros-Simó; Jessica Ruiz-Medina; Olga Valverde
Journal:  Psychopharmacology (Berl)       Date:  2011-12-06       Impact factor: 4.530

2.  Methamphetamine/amphetamine abuse and risk of Parkinson's disease in Utah: a population-based assessment.

Authors:  Karen Curtin; Annette E Fleckenstein; Reid J Robison; Michael J Crookston; Ken R Smith; Glen R Hanson
Journal:  Drug Alcohol Depend       Date:  2014-11-16       Impact factor: 4.492

Review 3.  (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies.

Authors:  U D McCann; V Eligulashvili; G A Ricaurte
Journal:  Neuropsychobiology       Date:  2000       Impact factor: 2.328

Review 4.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

Review 5.  Dopaminergic regulation of glutamic acid decarboxylase mRNA expression and GABA release in the striatum: a review.

Authors:  N Lindefors
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1993-11       Impact factor: 5.067

6.  Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings.

Authors:  U D McCann; Z Szabo; U Scheffel; R F Dannals; G A Ricaurte
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

7.  Biochemical and histological evidence that methylenedioxymethylamphetamine (MDMA) is toxic to neurons in the rat brain.

Authors:  D L Commins; G Vosmer; R M Virus; W L Woolverton; C R Schuster; L S Seiden
Journal:  J Pharmacol Exp Ther       Date:  1987-04       Impact factor: 4.030

8.  The effect of caffeine on MDMA-induced hydroxyl radical production in the mouse striatum.

Authors:  Anna Maria Górska; Karolina Noworyta-Sokołowska; Krystyna Gołembiowska
Journal:  Pharmacol Rep       Date:  2014-04-02       Impact factor: 3.024

9.  MDMA increases glutamate release and reduces parvalbumin-positive GABAergic cells in the dorsal hippocampus of the rat: role of cyclooxygenase.

Authors:  John H Anneken; Jacobi I Cunningham; Stuart A Collins; Bryan K Yamamoto; Gary A Gudelsky
Journal:  J Neuroimmune Pharmacol       Date:  2012-11-18       Impact factor: 4.147

10.  Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility.

Authors:  Lucia Frau; Nicola Simola; Antonio Plumitallo; Micaela Morelli
Journal:  J Neurochem       Date:  2012-11-15       Impact factor: 5.372

View more
  9 in total

1.  Repeated Administration of 3,4-Methylenedioxymethamphetamine (MDMA) Elevates the Levels of Neuronal Nitric Oxide Synthase in the Nigrostriatal System: Possible Relevance to Neurotoxicity.

Authors:  Giulia Costa; Micaela Morelli; Nicola Simola
Journal:  Neurotox Res       Date:  2018-04-09       Impact factor: 3.911

2.  The acute toxic and neurotoxic effects of 3,4-methylenedioxymethamphetamine are more pronounced in adolescent than adult mice.

Authors:  Neha Milind Chitre; Monique Simone Bagwell; Kevin Sean Murnane
Journal:  Behav Brain Res       Date:  2019-12-03       Impact factor: 3.332

Review 3.  Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy.

Authors:  Hans Emanuel Oeri
Journal:  J Psychopharmacol       Date:  2020-09-10       Impact factor: 4.153

4.  Three-dimensional telomere profiles in papillary thyroid cancer variants: A pilot study.

Authors:  Aline Rangel-Pozzo; Tinuccia Dettori; Daniela Virginia Frau; Federica Etzi; John Gartner; Garbor Fisher; Roberta Vanni; Sabine Mai; Paola Caria
Journal:  Bosn J Basic Med Sci       Date:  2022-06-01       Impact factor: 3.759

5.  Gender Differences in Neurodegeneration, Neuroinflammation and Na+-Ca2+ Exchangers in the Female A53T Transgenic Mouse Model of Parkinson's Disease.

Authors:  Giulia Costa; Maria Jose Sisalli; Nicola Simola; Salvatore Della Notte; Maria Antonietta Casu; Marcello Serra; Annalisa Pinna; Antonio Feliciello; Lucio Annunziato; Antonella Scorziello; Micaela Morelli
Journal:  Front Aging Neurosci       Date:  2020-05-07       Impact factor: 5.750

6.  Characterization of Nasco grape pomace-loaded nutriosomes and their neuroprotective effects in the MPTP mouse model of Parkinson's disease.

Authors:  Pathik Parekh; Marcello Serra; Mohamad Allaw; Matteo Perra; Jacopo Marongiu; Giulia Tolle; Annalisa Pinna; Maria Antonietta Casu; Maria Manconi; Pierluigi Caboni; Olivier J J Manzoni; Micaela Morelli
Journal:  Front Pharmacol       Date:  2022-08-17       Impact factor: 5.988

Review 7.  Involvement of the Protein Ras Homolog Enriched in the Striatum, Rhes, in Dopaminergic Neurons' Degeneration: Link to Parkinson's Disease.

Authors:  Marcello Serra; Annalisa Pinna; Giulia Costa; Alessandro Usiello; Massimo Pasqualetti; Luigi Avallone; Micaela Morelli; Francesco Napolitano
Journal:  Int J Mol Sci       Date:  2021-05-18       Impact factor: 5.923

Review 8.  Neuronal and peripheral damages induced by synthetic psychoactive substances: an update of recent findings from human and animal studies.

Authors:  Giulia Costa; Maria Antonietta De Luca; Gessica Piras; Jacopo Marongiu; Liana Fattore; Nicola Simola
Journal:  Neural Regen Res       Date:  2020-05       Impact factor: 5.135

9.  The Effects of 3,4-methylenedioxymethamphetamine on Neurogenesis in the Hippocampus of Male Rats.

Authors:  Sara Soleimani Asl; Fahimeh Ghasemi Moravej; Golshad Kowsari; Mohammad Hassan Farhadi; Bagher Pourhaydar; Hatef Ghasemi Hamidabadi; Mehdi Mehdizadeh
Journal:  Basic Clin Neurosci       Date:  2020-07-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.